|1.||Dolezal, J: 3 articles (01/2007 - 01/2000)|
|2.||Anderson, Peter M: 2 articles (01/2014 - 10/2005)|
|3.||Sinzinger, H: 2 articles (08/2011 - 06/2001)|
|4.||Scott, Tammy: 2 articles (12/2010 - 06/2009)|
|5.||Wharam, Moody D: 2 articles (12/2010 - 06/2009)|
|6.||Sgouros, George: 2 articles (12/2010 - 06/2009)|
|7.||Loeb, David M: 2 articles (12/2010 - 06/2009)|
|8.||Schwartz, Cindy L: 2 articles (12/2010 - 06/2009)|
|9.||Shokek, Ori: 2 articles (12/2010 - 06/2009)|
|10.||Hobbs, Robert F: 2 articles (12/2010 - 06/2009)|
|1.||Neoplasm Metastasis (Metastasis)
08/01/1995 - "Samarium-153-EDTMP is an effective agent for palliation of widespread skeletal metastases because it concentrates in bone metastases which have an osteoblastic component. "
09/01/2001 - "The present authors have developed a whole-body scintigraphic technique which is simple and reliable in calculating prospectively a safe and effective dose of 153Sm-EDTMP for palliating the patient's painful bone metastases without myelotoxicity."
09/01/1997 - "The results suggest that the 1.0 mCi/kg dose of 153Sm-EDTMP is safe and effective for the treatment of painful bone metastases."
04/01/2007 - "The aim of this study was to compare the analgesic effect of radionuclide therapy using Sr and Sm-EDTMP in patients with painful bone metastases of these tumours. "
11/01/2006 - "This study was to compare 3D absorbed dose calculation of 153Sm-EDTMP in treating a specified patient with bone metastasis between MC and S value methods. "
07/01/2007 - "The results of this study confirm that 153Sm-EDTMP is effective in terms of pain relief and PSA response, with minimal toxicity. "
07/01/2002 - "153Sm-EDTMP is a radiopharmaceutical used in nuclear medicine for relief of metastatic bone pain with promising results, but there are few studies about the effects of 153Sm-EDTMP in human cells. "
12/01/1989 - "Pain was relieved in 22 of 34 evaluable patients (65%) for periods ranging from 4 to 35 weeks, following a single administration of 153Sm-EDTMP. "
06/01/2010 - "We opted to combine (153)Samarium ethylenediaminetetramethylenephosphonate ((153)Sm-EDTMP), a radiopharmaceutical approved for the palliation of pain caused by metastatic bone lesions, with HDM and ASCT in a Phase II study. "
12/01/2004 - "The aim of this study was to evaluate the degree of metastatic bone pain palliation and medullar toxicity associated with samarium-153-EDTMP treatment. "
|3.||Prostatic Neoplasms (Prostate Cancer)
01/01/2005 - "The 188Re-HEDP group included 6 patients and 25 patients, and the 153Sm-EDTMP group 6 patients and 9 patients with breast and prostate cancer, respectively. "
06/01/2001 - "Complete scintigraphic lesion regression after single 153Sm-EDTMP therapy in prostate cancer."
11/01/2012 - "[Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis]."
11/01/2012 - "153Sm-EDTMP is an ideal agent for the treatment of prostate cancer with bone metastasis."
06/01/2005 - "[Cost-effectiveness analysis of samario-153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases]."
|4.||Osteosarcoma (Osteogenic Sarcoma)
12/01/2010 - "The authors conducted a phase 2 study to test safety and response of high-risk osteosarcoma to tandem doses of 153Sm-EDTMP and to determine correlation between radiation delivered by low and high administered activities. "
06/01/2009 - "Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma."
02/01/2008 - "Osteosarcoma often occurs in children, and previous studies on a juvenile rabbit model demonstrated that clinically significant damage to developing physeal cartilage may occur as a result of systemic 153 Sm-EDTMP therapy. "
12/01/2005 - "Human osteosarcoma most frequently occurs in skeletally immature individuals, and previous studies in a juvenile rabbit model demonstrated that clinically significant damage to developing physeal cartilage might occur as a result of systemic 153Sm-EDTMP therapy. "
07/01/2012 - "This would mean that, even at high level, 153Sm-EDTMP is itself ineffective against relapsed osteosarcoma or the residual activity is too low to be active on these particular subsets of patients."
|5.||Breast Neoplasms (Breast Cancer)
10/01/2003 - "To explore the therapeutic efficacy of 153Sm-EDTMP in treating painful bone metastases from breast cancer. "
10/01/2003 - "153Sm-EDTMP is safe and effective for fast palliation of painful bone metastases and for inhibition of metastatic foci from breast cancer."
10/01/2003 - "[Evaluation of efficacy of 153Sm-EDTMP in patients with painful bone metastases of breast cancer]."
02/01/2009 - "The aim of this study was to assess the usefulness of (153)samarium-ethylene-diamino-tetramethylene phosphonic acid ((153)Sm-EDTMP, a beta and gamma emitter) treatment in the palliation of painful bone metastases from breast cancer. "
10/01/2003 - "Seventy-six patients with painful bone metastases from breast cancer entered the study and were treated by intravenous administration of 153Sm-EDTMP in two doses. "
|2.||zoledronic acid (zoledronate)
|6.||Prostate-Specific Antigen (Semenogelase)
|2.||Palliative Care (Palliative Medicine)
|3.||Drug Therapy (Chemotherapy)